Sign in

    Immunitybio Inc (IBRX)

    Q1 2025 Earnings Summary

    Reported on Jan 1, 1970 (Before Market Open)
    Pre-Earnings Price$2.26Open (May 12, 2025)
    Post-Earnings Price$2.26Open (May 12, 2025)
    Price Change
    $0.00(0.00%)
    MetricYoY ChangeReason

    Total Revenue

    41,250% increase (from $0.04M in Q1 2024 to $16.5M in Q1 2025)

    Q1 2025’s surge in Total Revenue is driven by the company’s transition to full product commercialization. In Q1 2024, revenues were minimal, while by Q1 2025, product revenue became the sole contributor, reflecting increased customer adoption and robust market entry.

    Product Revenue, Net

    Not separately quantified; now the sole revenue component

    The switch to Product Revenue, Net as the only reported revenue line in Q1 2025 highlights successful commercialization. Previously, the company generated negligible revenues due to an undeveloped product pipeline, and the current focus underscores a major strategic milestone.